U.S. Supreme Court Rejects Amgen Over Cholesterol Medication Patent Fight

www.oann.com | 10/21/2013 | Staff
ridge-khridge-kh (Posted by) Level 4
WASHINGTON (Reuters) – The U.S. Supreme Court on Monday declined to take up Amgen Inc’s bid to reinstate a jury verdict it won against rivals Regeneron Pharmaceuticals Incand Sanofi SAin patent dispute over cholesterol medication.

The justices turned away Amgen’s appeal of a 2017 decision by a lower court to set aside a jury’s verdict that two Amgen patents were valid and nullify a ban on sales of Regeneron and Sanofi SA’s cholesterol-lowering drug Praluent.

Amgen - US - Court

Amgen had argued that the U.S. Court of...
(Excerpt) Read more at: www.oann.com
Wake Up To Breaking News!
Millions in tribute, but not a penny left for charity.
Sign In or Register to comment.

Welcome to Long Room!

Where The World Finds Its News!